Inno Holdings Inc. (INHD) competitors & alternatives
Industrials · NASDAQ
Inno Holdings Inc. (INHD)'s top competitors and alternatives — its most similar public companies — include SWARMER INC (SWMR), AIRJOULE TECHNOLOGIES CORP CLASS A (AIRJ), PALLADYNE AI CORP (PDYN), Boost Run Inc. (BRUN), SAVARA INC (SVRA), DIANTHUS THERAPEUTICS INC (DNTH), EVOMMUNE INC (EVMN), PALISADE BIO INC (PALI), PUMA BIOTECHNOLOGY INC (PBYI), EIKON THERAPEUTICS INC (EIKN), ARTIVA BIOTHERAPEUTICS INC (ARTV) and Veeva Systems (VEEV). These are Inno Holdings Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top INHD competitors & alternatives
-
SWARMER INCSWMRIndustrials
Swarmer Inc is an early-stage company currently working to develop and commercialize its products while managing significant operating losses and high customer…
$41.12 (as of 2026-07-22) · market cap $446M
-
AIRJOULE TECHNOLOGIES CORP CLASS AAIRJIndustrials
A pre-revenue clean technology company developing advanced energy systems through its AirJoule technology platform.
$4.60 (as of 2026-07-22) · market cap $333M
-
PALLADYNE AI CORPPDYNIndustrials
Early-stage AI-driven industrial software company developing products for automation and operational intelligence, currently pre-profitability with significant…
$5.33 (as of 2026-07-22) · market cap $248M
-
Boost Run Inc.BRUNInformation Technology
An emerging SaaS company at the early commercialization stage tracking recurring revenue and contracted backlog with recent public market entry.
$24.22 (as of 2026-07-22) · market cap $1.9B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
DIANTHUS THERAPEUTICS INCDNTHHealth Care
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and…
$102.76 (as of 2026-07-22) · market cap $5.7B
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
PALISADE BIO INCPALIHealth Care
A clinical-stage biotech developing PALI-2108, a licensed small-molecule candidate in Phase 1 trials, with a capital-dependent model dependent on licensing…
$1.90 (as of 2026-07-22) · market cap $331M
-
PUMA BIOTECHNOLOGY INCPBYIHealth Care
Biopharmaceutical company commercializing NERLYNX (neratinib), an irreversible HER2 tyrosine kinase inhibitor for HER2-positive breast cancer, and developing…
$7.87 (as of 2026-07-22) · market cap $418M
-
EIKON THERAPEUTICS INCEIKNHealth Care
A clinical-stage biopharmaceutical company utilizing a proprietary technology platform to discover and develop a pipeline of novel therapeutic candidates.
$9.61 (as of 2026-07-22) · market cap $525M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
-
Veeva SystemsVEEVHealth Care
Veeva is the dominant cloud software and data platform powering the global life sciences industry from drug development through commercialization, with…
$184.55 (as of 2026-07-22) · market cap $29.8B
Not quite? Describe exactly what you want →
Peers are Inno Holdings Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Inno Holdings Inc. (INHD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.